The main purpose of this study is to determine whether nivolumab + chemotherapy is effective as compared to chemotherapy in the treatment of patients with EGFR mutation, NSCLC who failed first line (1L) or second-line (2L) EGFR TKI therapy.
Name: Nivolumab
Type: BiologicalNivolumab + Ipilimumab Nivolumab+Platinum doublet chemotherapy
Name: Ipilimumab
Type: BiologicalNivolumab + Ipilimumab
Name: Pemetrexed
Type: DrugNivolumab+Platinum doublet chemotherapy Platinum doublet chemotherapy
Name: Cisplatin
Type: DrugNivolumab+Platinum doublet chemotherapy Platinum doublet chemotherapy
Name: Carboplatin
Type: DrugNivolumab+Platinum doublet chemotherapy Platinum doublet chemotherapy
Allocation: Randomized
Parallel Assignment
There is one SNP
- No evidence of exon 20 T790M mutation obtained at progression on prior first- or second-generation EGFR TKI therapy. --- T790M ---
For subjects who were treated with osimertinib, T790M testing is not required. --- T790M ---
- Eastern Cooperative Group (ECOG) Performance Status 0-1 - Life expectancy is at least 3 months Exclusion Criteria: - Subjects with known EGFR mutation, T790M positive who failed 1L first- or second-generation TKI should receive osimertinib first as the standard of care (SOC). --- T790M ---